P-32 bremsstrahlung SPECT helps assess intracavitary therapy

Our plain-English summary of P-32 bremsstrahlung SPECT helps assess intracavitary therapy, by B. Petri, R. Nance, J. Hanada, et al (Clinical Nuclear Medicine, 1992).

The study

• Authors: B. Petri, R. Nance, J. Hanada, J. Stevens
• Journal: Clinical Nuclear Medicine
• Published: 1992;17(9):709-10
• Type of article: Case report
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

A patient underwent intracavitary P-32 chromic phosphate therapy for a chest tumor. Tc-99m sulfur colloid instilled before the P-32 demonstrated uniform distribution of activity throughout the right pleural space, and the P-32 was immediately administered. Ten days later, SPECT imaging using bremsstrahlung radiation of the P-32 showed an unexpected loculation of the P-32. A subsequent chest CT scan demonstrated pleural infolding and fluid localization in the same area as the P-32, indicating that the bremsstrahlung SPECT study had, in fact, documented the final localization of the P-32, which was unexpected and different from the initial localization. The procedure used in this case may be of value in documenting the ultimate distribution of intracavitary P-32.

In plain English

This article was a case report of one patient seen at Oregon Health Sciences University in Portland, Oregon. The patient was a 74-year-old man with recent shortness of breath and new fluid around the lung. A mesothelioma was diagnosed by examining cells in that pleural fluid. The article did not discuss asbestos exposure. He was given 15 mCi of P-32 chromic phosphate, a radioactive treatment, into the right pleural space, the space around the right lung. Just before that, a tracer (Tc-99m sulfur colloid) showed an even spread throughout that space. Ten days later, a SPECT scan that detected radiation given off by the P-32 showed it apparently collected in one pocket at the back and inner part of the right chest. Ordinary chest X-rays taken at the same time showed nothing to explain this. A CT scan 26 days later found pocketed pleural fluid in an inward fold of the pleura at the back of the lung, in the same area. The authors concluded this appeared to be a simple way to document where P-32 finally ends up, which apparently cannot be predicted accurately from its initial spread.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: case report (one patient)
• Who was studied: One 74-year-old man with recent shortness of breath and a new pleural effusion, who had a mesothelioma diagnosed by pleural fluid cytology. He was treated at the Division of Nuclear Medicine, Oregon Health Sciences University, Portland, Oregon. The article does not give treatment dates; it was received for publication in November 1991.
• Exposure: The article does not describe any asbestos exposure. What it studied was the treatment: 15 mCi of P-32 chromic phosphate instilled into the right pleural space, given right after 1 mCi of Tc-99m sulfur colloid used to check how fluid spread in that space.
• Main results:
  • At the time of instillation, the Tc-99m sulfur colloid images showed an even spread throughout the patient's right pleural space.
  • Ten days later, SPECT imaging of the P-32 bremsstrahlung radiation showed the P-32 apparently collected in one pocket in the posteromedial (back and inner) part of the right chest. The authors described this as surprising.
  • Standard frontal and lateral chest X-rays taken at the same time as the SPECT study showed no focal abnormality that would explain this.
  • A chest CT scan done 26 days later, for planning external beam radiation therapy, showed pocketed pleural fluid in an inward fold of the posterior visceral pleura. The authors said this matched very well the location of the P-32 seen on SPECT.
• The authors' conclusion: The authors concluded that bremsstrahlung SPECT appeared to be a simple way to document where P-32 is finally distributed, which apparently cannot be predicted accurately from where it first spreads.
• Limitations the authors state:
  • The authors stated that the reason for the CT finding (the pocket of pleural fluid) was unclear.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: CT Scan.

Related studies

• Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest — A. Raben, B. Mychalczak (1997)
• Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors — R. Misri, K. Saatchi, et al. (2011)
• High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy — L.A. Doyle, T.N. Showalter, et al. (2010)
• Radiation therapy in the management of patients with mesothelioma — W. Gordon, K.H. Antman, et al. (1982)
• Unusual radiologic findings in the thorax after radiation therapy — B. Mesurolle, S.D. Qanadli, et al. (2000)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies — S. Kiesgen, L. Chicaybam, et al. (2018)

Browse more research in Clinical Nuclear Medicine, or return to medical research.